Clinical application of stem cells for therapeutic angiogenesis in patients with peripheral arterial disease

International Journal of Stem Cells

Volumn 2, Issue 1, 2009, Pages 11-17

  Lee, Kyung Bok ^a   Kim, Dong Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Peripheral arterial disease; Stem cells

Indexed keywords

EID: 80051586852     PISSN: 20053606     EISSN: 20055447     Source Type: Journal    
DOI: 10.15283/ijsc.2009.2.1.11     Document Type: Review

References (43)

1. Criqui MH. Peripheral vascular disease-epidemiological aspects. Vasc Med 2001;3 Suppl 6:3-7.
2. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Godman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-515.
3. Fowkes FGR, Housley E, Cawood EH, Macintyre CA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20:384-392.
4. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U. Epidemiology of intermittent claudication in middleaged men. Am J Epidemiol 1994;140:418-430.
5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997;96:44-49.
6. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18: 185-192.
7. He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg 2006;44:333-338.
8. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985;33:13-18.
9. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-743.
10. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45 Suppl:S5-S67.
11. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Oline JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-654.
12. Ubbink DT, Tulevski II, den Hartog D, Koelemay MJ, Legemate DA, Jacobs MJ. The value of non-invasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg 1997;13:296-300.
13. Arain FA, Leslie T, Copper JR. Peripheral Arterial Disease: Diagnosis and Management. Mayo Clin Proc 2008; 83:944-950.
14. Al Mheid I, Quyyumi AA. Cell therapy in peripheral arterial disease. Angiology 2009;59:705-716.
15. Olin JW. Thromboangiitis obliterans (Buerger's disease). In: Cecel Medicine. 23th ed. Philadelphia: Saunders ELSEVIER; 2008. 570.
16. Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000;343:864-869.
17. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45-55.
18. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000:6:389-395.
19. Schaper W, Ito WD. Molecular mechanism of coronary vessel growth. Circ Res 1996;79:911-919.
20. Collinson DJ, Donnelly R. Therapeutic anigogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 2004;25:9-23.
21. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-1066.
22. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
23. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-1397.
24. Kim MJ, Kim MH, Kim SA, Chang JS. Age-related deterioration of hematopoietic stem cells. International J Stem Cells 2008;1:55-63.
25. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J. Clinical applications of bloodderived and morrow-derived stem cells for nonmalignant disease. JAMA 2008;299:925-936.
26. Kaji EH, Leiden JM. Gene and stem cell therapies. JAMA 2001;285:545-550.
27. Ko IK, Kim BS. Mesenchymal stem cells for treatment of myocardial infarction. International J Stem Cells 2008;1: 49-54.
28. Kim SU, Lee HJ, Park IH, Chu K, Lee ST, Kim NH, Roh JK, Kim SK, Wang KC. Human neural stem cells for brain repair. International J Stem Cells 2008;1:27-35.
29. Kørbling M, Estrov Z. Adult stem cells for tissue repair-a new therapeutic concept? N Engl J Med 2003;349:570-582.
30. Lee KB, Kim AK, Kim MJ, Do YS, Shin SW, Kim JS, Park CJ, Kang KS, Kim BS, Joh JH, Oh WI, Hong HK, Kim DI. Angiogenesis induced by autologous whole bone marrow stem cells transplantation. International J Stem Cells 2008; 1:64-69.
31. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
32. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entam ML, Michael LH, Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107:1395-1402.
33. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized controlled trial. Lancet 2002;360:427-435.
34. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomized clinical trial. Lancet 2004;363:751-756.
35. Miyamoto K, Nishigami K, Nagaya N, Akutsu K, Chiku M, Soma T, Miyata Sm, Higashi M, Tanaka R, Nakatani T, Nonogi H, Takeshita S. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006;114: 2679-2684.
36. Hirsch AT. Critical limb ischemia and stem cell research: informed adverse event reporting anchoring hope with informed adverse event reporting. Circulation 2006; 114: 2581-2583.
37. Miyamoto M, Yasutake M, Takano H, Takagi H, Takagi G, Mizuno H, Kumita S, Takano T. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetroformin (TF) perfusion scintigraphy. Cell Transplant 2004;13:429-437.
38. Kawamura A, Horie T, Tsuda I, Ikeda A, Egawa H, Imamura E, Iida J, Sakata H, Tamaki T, Kukita K, Meguro J, Yonekawa M, Kasai M. Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 2005;9: 59-63.
39. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28:2155-2160.
40. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006;9:226-233.
41. Bartsch T, Falke T, Brehm M, Zeus T, Kögler G, Wernet P, Strauer BE. Transplantation of autologous adult bone marrow stem cells in patients with severe peripheral arterial occlusion disease. Med Klin (Munich) 2006;101 Suppl 1: 195-197.
42. Kim DI, Kim MJ, Joh JH, Shin SW, Do YS, Moon JY, Kim NR, Lim JE, Kim AK, Eo HS, Kim BS, Cho SW, Yang SH, Park CJ, Shim JS. Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease. Stem Cells 2006;24:1194-1200.
43. Durdu S, Akar AR, Arat M, Sancak T, Eren NT, Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006;44:732-739.